Epizyme Achieves $4 Mln in Pre-Clinical Milestone Payments in GlaxoSmithKline Alliance to Discover and Develop Novel HMT Therapeutics.

GlaxoSmithKline; Epizyme Inc.; Strategic alliances (Business); Cancer patients; Cancer treatment; Histone methyltransferases

The article reports on the pre-clinical milestone achieved by Epizyme Inc. in the U.S. together with GlaxoSmithKline. It states that the two companies entered into a strategic alliance to discover, develop and market small molecule therapeutics that target histone methyltransferases (HMTs) for the treatment of cancer and other diseases. It notes that the alliance provides further validation of Epizyme's ability to discover small molecule histone methyltransferase inhibitors for cancer patients.